TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10939702
Drug: Oral dextromethorphan
Normalized name: dextromethorphan Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dextromethorphan 120 mg
Study: 10939702
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ibuprofen 400 mg and dextromethorphan 120 mg
Study: 1350481
Drug: Carvedilol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (100 mg)
Study: 4007027
Drug: Bay g
Normalized name: ALCOHOL 70 L in 100 L TOPICAL GEL [Victoria Bay Gel Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bay g 2821 (muzolimine)
Study: 27663186
Drug: Symptom management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptom management (SM) drugs
Study: 27663186
Drug: Disease management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease management (DM) drugs
Study: 18162083
Drug: IV esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV esomeprazole 40 mg
Study: 18162083
Drug: IV lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV lansoprazole 30 mg
Study: 11111131
Drug: Whole-leaf spinach,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-leaf spinach, minced spinach, liquefied spinach, liquefied spinach with dietary fibre (10 g/kg wet weight)
Study: 11111131
Drug: Synthetic carotenoid
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic carotenoid supplement
Study: 8617114
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (bismuth, metronidazole, tetracycline) for one week
Study: 8617114
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (amoxicillin and omeprazole) for two weeks
Study: 22971493
Drug: L-CCB
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-CCB
Study: 16085251
Drug: Lumbar epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar epidural tramadol (100 mg)
Study: 16085251
Drug: Lumbar epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar epidural morphine (4 mg)
Study: 9053503
Drug: Etoposide phosphate
Normalized name: Etoposide Phosphate
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide phosphate (EP) at 10 mg/m2/d
Study: 9053503
Drug: Etoposide phosphate
Normalized name: Etoposide Phosphate
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide phosphate (EP) at 20 mg/m2/d
Study: 9053503
Drug: Etoposide phosphate
Normalized name: Etoposide Phosphate
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide phosphate (EP) at 25 mg/m2/d
Study: 9053503
Drug: Etoposide phosphate
Normalized name: Etoposide Phosphate
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide phosphate (EP) at 30 mg/m2/d
Study: 3940830
Drug: Intravenous theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous theophylline (100 mg) with T.E.
Study: 3940830
Drug: Intravenous theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous theophylline (200 mg) with T.E.
Study: 3940830
Drug: Intravenous theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous theophylline (351 mg) with T.E.
Study: 3940830
Drug: Intravenous theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous theophylline (200 mg) with T.P.D.
Study: 29402513
Drug: Autologous platelet-rich
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous platelet-rich fibrin (PRF) placed in the peri-implant region (n=21)
Study: 29402513
Drug: No augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No augmentation (control group, n=20)
Study: 27737744
Drug: Canakinumab 150
Normalized name: canakinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canakinumab 150 mg monthly for 12 months
Study: 24795254
Drug: RO5093151 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO5093151 (200 mg twice daily)
Study: 23103618
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of modafinil orally
Study: 18595969
Drug: Placebo (oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oil droplets from gelatinous capsule)
Study: 16080445
Drug: Food supplemented
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food supplemented with vitamin C (from kiwi fruits) and vitamin E (in capsules)
Study: 12565115
Drug: Sufentanil bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil bolus at 0.5 microg kg(‐1) and continuous infusion at 0.5 microg kg h(‐1) stopped when the tourniquet was released (Group 1, n=6)
Study: 12565115
Drug: Sufentanil bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil bolus at 0.5 microg kg(‐1) and continuous infusion at 0.5 microg kg h(‐1) stopped 15 minutes after tourniquet release (Group 2, n=6)
Study: 30346860
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg OD at 8:00 AM
Study: 30346860
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg OD at 8:00 PM
Study: 30346860
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg BID at 8:00 AM and PM
Study: 23357031
Drug: Ethanol at
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol at BAC levels of 0.5g/L and 0.9g/L
Study: 23357031
Drug: Placebo drinks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drinks and placebo pills
Study: 9570192
Drug: Combined hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined hormone replacement therapy
Study: 3054626
Drug: Amitriptyline 25
Normalized name: amitriptyline 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 25 mg bid
Study: 31904760
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (60 g/day) with high-fiber wheat bran (30 g fiber/day)
Study: 31904760
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (60 g/day) with low-fiber refined wheat (10 g fiber/day)
Study: 31904760
Drug: Maltodextrin with
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrin with high-fiber wheat bran (30 g fiber/day)
Study: 31904760
Drug: Maltodextrin with
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrin with low-fiber refined wheat (10 g fiber/day)
Study: 12706935
Drug: Bosentan (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan (125 or 250 mg twice daily)
Study: 11022397
Drug: Tropicamide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropicamide (20 microL, 0.01%) administered to one eye and placebo to the other.
Study: 11022397
Drug: Scopolamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (0.5 mg, intravenously) administered in separate sessions.
Study: 8612392
Drug: Phenytoin 300
Normalized name: phenytoin 300 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenytoin 300 mg daily
Study: 6692384
Drug: Hydrazine sulfate
Normalized name: Hydrazine Sulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrazine sulfate (60 mg, 3 times/day for 30 days)
Study: 29122709
Drug: Letrozole (10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (10mg daily for 3 days) followed by vaginal misoprostol
Study: 23282127
Drug: Nebivolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol (5 mg per day)
Study: 27113048
Drug: Metoprolol succinate
Normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol succinate (100 mg per day)
Study: 23707383
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT), n=50
Study: 12821232
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 0.5 mg/day
Study: 10826403
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 to 10 mg daily)
Study: 30570309
Drug: CBTsa (Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBTsa (Cognitive Behavioral Therapy for social activation)
Study: 26016955
Drug: Grief intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Grief intervention treatment group
Study: 21276961
Drug: Extended-release niacin
Normalized name: niacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release niacin monotherapy (48 weeks; n=31)
Study: 12743670
Drug: Quinine hydrochloride
Normalized name: quinine hydrochloride
DrugBank: Quinine (DB00468)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinine hydrochloride 250 mg alone
Study: 12743670
Drug: Quinine hydrochloride
Normalized name: quinine hydrochloride
DrugBank: Quinine (DB00468)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinine hydrochloride 250 mg with four other CYP probe drugs
Study: 12743670
Drug: Quinine hydrochloride
Normalized name: quinine hydrochloride
DrugBank: Quinine (DB00468)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinine hydrochloride 250 mg with ketoconazole
Study: 12743670
Drug: Quinine hydrochloride
Normalized name: quinine hydrochloride
DrugBank: Quinine (DB00468)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinine hydrochloride 250 mg with fluvoxamine
Study: 29338584
Drug: βHB salts
Approvals — FDA: no, EMA: no, PMDA: no
Description: βHB salts (0.38 g kg body mass‐1) in plain water (3.8 mL kg body mass‐1)
Study: 29338584
Drug: plain water
Approvals — FDA: no, EMA: no, PMDA: no
Description: plain water (3.8 mL kg body mass‐1) (CON)
Study: 21368750
Drug: rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone 4 mg b.i.d. for 9 weeks
Study: 16490809
Drug: Ezetimibe (EZE)
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe (EZE) 10 mg coadministered with CyA (75-150 mg twice a day)
Study: 16490809
Drug: Ezetimibe (EZE)
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe (EZE) 10 mg with CyA
Study: 14508021
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (received information about pain relieving injection)
Study: 14508021
Drug: Nocebo group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nocebo group (received information about pain increasing injection)
Study: 14508021
Drug: Natural History
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural History group (received no information and no injection)
Study: 11191179
Drug: Flumazenil 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil 2.5 mg
Study: 11191179
Drug: Flumazenil 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil 5.0 mg
Study: 11191179
Drug: Flumazenil (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (all doses)
Study: 3095507
Drug: Empirical mannitol
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Empirical mannitol therapy irrespective of ICP readings
Study: 29332056
Drug: Percutaneous ozone
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous ozone injection alone (Control)
Study: 29332056
Drug: Combined ozone
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined ozone injection and percutaneous microdiscectomy (Treatment)
Study: 27476806
Drug: Long-acting injectable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting injectable second-generation antipsychotic
Study: 27476806
Drug: Oral second-generation
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral second-generation antipsychotic
Study: 27476806
Drug: Long-acting injectable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting injectable medication administration schedule
Study: 22324458
Drug: Standardized assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized assessment and evidence-based treatment for urinary incontinence
Study: 20399995
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation A (valsartan 160 mg)
Study: 20399995
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation B (valsartan 160 mg)
Study: 20399995
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (valsartan 160 mg)
Study: 18512043
Drug: Euglycaemia (blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglycaemia (blood glucose level at 5 mmol/l)
Study: 18512043
Drug: Hyperglycaemia (blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycaemia (blood glucose level at 11 mmol/l)
Study: 17310949
Drug: DNAase treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNAase treatment
Study: 14671698
Drug: Contrast-enhanced duplex
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast-enhanced duplex ultrasound (Definity, infused at 2 to 4 mL/min)
Study: 9179187
Drug: Androgen ablation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen ablation therapy (AAT)
Study: 9179187
Drug: No androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: No androgen ablation therapy (no AAT)
Study: 1350140
Drug: Subcutaneous interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous interferon alpha 2a plus cryotherapy
Study: 2859970
Drug: Terbutaline, 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline, 0.5 mg intravenously
Study: 2859970
Drug: Prenalterol, 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenalterol, 1.0 and 4.0 mg intravenously
Study: 28535438
Drug: Edoxaban 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 90 mg
Study: 28535438
Drug: Edoxaban 60
Normalized name: edoxaban 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 60 mg in sodium citrate tubes
Study: 28535438
Drug: Edoxaban 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 90 mg in sodium citrate tubes
Study: 25732165
Drug: Cytarabine 200
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytarabine 200 mg/m2 continuous IV infusion once per day on days 1 to 7 plus amonafide 600 mg/m2 IV over 4 hours on days 1 to 5 (A + C arm)
Study: 25732165
Drug: Cytarabine 200
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytarabine 200 mg/m2 continuous IV infusion once per day on days 1 to 7 plus daunorubicin 45 mg/m2 IV over 30 minutes once per day on days 1 to 3 (D + C arm)
Study: 21790765
Drug: N-butylscopolammonium bromide
Normalized name: N-butylscopolammonium
DrugBank: Butylscopolamine (DB09300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-butylscopolammonium bromide (NBB) 0.3 mg/kg bwt i.v.
Study: 21790765
Drug: Xylazine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylazine 0.25 mg/kg bwt i.v.
Study: 21790765
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of NBB (0.3 mg/kg bwt) and xylazine (0.25 mg/kg bwt) i.v.
Study: 19561254
Drug: US-guided percutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: US-guided percutaneous treatment
Study: 16756418
Drug: Medication contingency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication contingency group
Study: 8222516
Drug: Noradrenaline infusion
Normalized name: noradrenaline hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noradrenaline infusion (0.015 to 0.075 microgram min‐1 kg‐1) during euhydration
Study: 8222516
Drug: Noradrenaline infusion
Normalized name: noradrenaline hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noradrenaline infusion (0.015 to 0.075 microgram min‐1 kg‐1) during overhydration
Study: 2939869
Drug: Doxazosin 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin 16 mg daily
Study: 26255249
Drug: Rituximab (RTX)
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab (RTX) monotherapy
Study: 21497708
Drug: Pomegranate juice
Normalized name: pomegranate juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate juice (200 mL twice daily for 2 weeks)
Study: 17133780
Drug: Nourkrin (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nourkrin (active preparation)
Study: 29866011
Drug: Triflusal 300
Normalized name: triflusal 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triflusal 300 mg twice daily or 600 mg once daily
Study: 20199764
Drug: 23-valent pneumococcal
Normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23-valent pneumococcal polysaccharide vaccine (PPV-23)
Study: 18043484
Drug: 800‐mg oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800‐mg oral dose of EGCG administered as Polyphenon E under fasting conditions
Study: 18043484
Drug: 800‐mg oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800‐mg oral dose of EGCG administered as Polyphenon E under fed conditions
Study: 16251628
Drug: Supplementation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementation of breast‐feeding mothers with 60 mg retinol equivalent (RE) vitamin A within 4 wk of delivery
Study: 16251628
Drug: EPI‐linked supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPI‐linked supplementation of infants with 7.5 mg RE vitamin A at 6, 10, and 14 wk
Study: 1758201
Drug: terbutaline 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: terbutaline 0.5 mg inhaled through a cone spacer with positive expiratory pressure (+PEP)
Study: 1758201
Drug: terbutaline 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: terbutaline 0.5 mg inhaled through a cone spacer without positive expiratory pressure (‐PEP)
Study: 7093597
Drug: Oral amitriptyline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amitriptyline (75-225 mg/day)
Study: 7093597
Drug: Intramuscular flupenthixol
Normalized name: flupenthixol
DrugBank: Flupentixol (DB00875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular flupenthixol decanoate (10-30 mg every 14 days)
Study: 31526640
Drug: New domestic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New domestic dacron patch
Study: 31526640
Drug: Imported cardiac
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imported cardiac polyester patch
Study: 28838955
Drug: Bosutinib 200
Normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bosutinib 200 mg/d
Study: 28838955
Drug: Pooled bosutinib
Normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pooled bosutinib (200 mg/d and 400 mg/d)
Study: 24830824
Drug: Dexamethasone intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone intravitreal implant 0.7 mg (DEX implant)
Study: 19736426
Drug: Dexamethasone-cyclophosphamide pulse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone-cyclophosphamide pulse and daily oral cyclophosphamide (DCP+C)
Study: 19736426
Drug: Cyclophosphamide pulse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide pulse and daily oral prednisolone (CP+P)
Study: 10923750
Drug: Zotepine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zotepine (300 mg daily, with fallback to 150 mg if necessary)
Study: 1590226
Drug: Amiodarone 200
Normalized name: amiodarone 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone 200 mg/day
Study: 18479589
Drug: Chlorthalidone 6.25
Normalized name: Chlorthalidone 6.25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 6.25 mg + Atenolol 25 mg
Study: 18479589
Drug: Atenolol 25
Normalized name: atenolol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 25 mg + Amlodipine 2.5 mg
Study: 11009045
Drug: Mefloquine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine (500 mg, 250 mg, 250 mg over 12 h) followed by co-artemether (6 x 4 tablets over 60 h)
Study: 1405960
Drug: Canal preparation
Normalized name: Canal + Gel 10% for Root Canal Preparation Dental Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canal preparation with Betadine and alcohol
Study: 4057312
Drug: Haloperidol 5
Normalized name: haloperidol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 5 mg IM
Study: 24762109
Drug: Low-dose ethinyl
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ethinyl estradiol (EE2) during childhood (25 ng/kg/d for ages 5-8 years; 50 ng/kg/d for ages >8-12 years)
Study: 19515367
Drug: Paroxetine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine administration for 5 weeks
Study: 12450644
Drug: Buspirone combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone combined with non-directive therapy
Study: 12450644
Drug: Placebo combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo combined with non-directive therapy
Study: 8769497
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (CPAP and AMP)
Study: 30062946
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 2.0 g of TXA orally two hours preoperatively (group A)
Study: 30062946
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of TXA followed by 1.0 g orally three hours postoperatively (group B)
Study: 30062946
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of TXA followed by 1.0 g three and nine hours postoperatively (group C)